Treatment of Chemotherapy-Induced Nausea and Vomiting
Recent improvements in medical oncology include both development of anticancer and supportive therapy. Serotonin receptor antagonists were introduced in clinical practice 20 years ago. Since then, the prevention and treatment of chemotherapy-induced nausea and vomiting allows continuing efficacious chemotherapy that earlier had to be stopped sometimes for intolerance.
This anniversary review summarises the current antiemetic arsenal focussing on the most potent antiemetic drugs such as serotonin and substance P receptor antagonists.
Antiemetic treatment improves quality of life under chemotherapy and contributes to the survival benefit as well. In spite of the use of these new drugs, a significant number of patients still experience nausea and vomiting. Special complications like delayed emesis can be alleviated by combination therapies.
Prevention and optimal management of chemotherapy-induced nausea and vomiting should be a goal for most patients receiving emetogenic chemotherapy.
KeywordsAntiemetic Chemotherapy Nausea-vomiting
- 4.Mannix KA. Palliation of nausea and vomiting. CME Can Med. 2002;1(1):18–22.Google Scholar
- 5.Grunberg SM, Hesketh PJ. Control of chemotherapy-induced emesis. N Engl J Med 329:1790–96.Google Scholar
- 11.Réseau Oncolor Référenciels Anti-nauséeux et anti-émétiques [en ligne], 2003.Google Scholar
- 13.NCCN. National Comprehensive Cancer Network: Antiemesis, Clinical Practice Guidelines in Oncology-v.1. 2010. www.nccn.org (4 October 2010, date last accessed).
- 19.Lindley C, Blower P. Oral serotonin type 3-receptor antagonists for prevention of chemotherapy-induced emesis. Am J Health-Syst Pharm 57 (18): 1685–97.Google Scholar
- 29.Lofters WS, Pater JL, Zee B, et al. Phase III double-blind comparison of dolasetron mesylate and ondansetron and an evaluation of the additive role of dexamethasone in the prevention of acute and delayed nausea and vomiting due to moderately emetogenic chemotherapy. J Clin Oncol. 1997;15(8):2966–73.PubMedGoogle Scholar
- 33.Koizumi W, Tanabe S, Nagaba S, et al. A double-blind, crossover, randomized comparison of granisetron and ramosetron for the prevention of acute and delayed cisplatin-induced emesis in patients with gastrointestinal cancer: is patient preference a better primary endpoint? Chemotherapy. 2003;49(6):316–23.PubMedCrossRefGoogle Scholar
- 35.Gralla R, Lichinitser M, Van Der Vegt S, et al. Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron. Ann Oncol. 2003;14(10):1570–7.PubMedCrossRefGoogle Scholar
- 36.Eisenberg P, Figueroa-Vadillo J, Zamora R, et al. Palonosetron Study Group Improved prevention of moderately emetogenic chemotherapy-induced nausea and vomiting with palonosetron, a pharmacologically novel 5-HT3 receptor antagonist: results of a phase III, single-dose trial versus dolasetron. Cancer. 2003;98(11):2473–82.PubMedCrossRefGoogle Scholar
- 40.Gralla RJ, de Wit R, Herrstedt J, et al. Antiemetic efficacy of the neurokinin-1 antagonist, aprepitant, plus a 5HT3 antagonist and a corticosteroid in patients receiving anthracyclines or cyclophosphamide in addition to high-dose cisplatin: analysis of combined data from two Phase III randomized clinical trials. Cancer. 2005;104(4):864–8.PubMedCrossRefGoogle Scholar